



# Opioid Prescribing in Adults Excluding Palliative and End-of-Life Care

This guideline is intended to apply to patients aged ≥ 18 years with acute or chronic pain outside of palliative and end-of-life care.

Key Components	Recommendation and Level of Evidence											
Avoid starting opioids	Opioid Use Disorder (OUD) often begins with initial opioid exposure in treatment of acute pain and is associated with a substantial risk of chronic use in some patients. Treat pain with non-drug therapy (e.g., physical [acupuncture, massage] or behavioral modalities), and <a href="#">non-opioid medications</a> (e.g., acetaminophen, NSAIDs), if possible. Opioids are rarely useful in chronic pain management. Risks usually outweigh benefits. Consider buprenorphine if an opioid is considered appropriate for chronic pain treatment. Discuss patient's wishes specific to opioid use. Consider opioid therapy only if expected realistic benefits for both pain and function are anticipated to outweigh risks to the patient.											
Before starting opioids, assess risk of dependence, overdose or death	Review history of controlled substance use, mental health and substance misuse. Obtain a Prescription Drug Monitoring Program (PDMP) report, (i.e., <a href="#">MAPS</a> ). Document this review. Refer to local laws <sup>1</sup> Screen for risk of OUD; consider using an instrument such as <a href="#">SOAPP-R</a> , <a href="#">ORT</a> , <a href="#">TAPS</a> , or <a href="#">NIDA Quick Screen</a> . There is no safe lower limit of dose or duration for opioid use. After seven days of use, the risk of chronic use rises 3-4 fold. Discuss the <a href="#">risks of opioid use</a> including physical dependency, overdose, OUD, addiction, drug and alcohol interactions, effects of fetal exposure/toxicity for females of reproductive age, <a href="#">proper disposal of unused opioids</a> , and that diversion (sharing or selling) of a controlled substance is a felony in Michigan. Discuss lack of evidence of superiority to NSAIDs. <b>[B4]</b>	<table border="1"> <thead> <tr> <th>MME/day</th> <th>Relative risk of death</th> </tr> </thead> <tbody> <tr> <td>20-49</td> <td>1.3</td> </tr> <tr> <td>50-99</td> <td>1.9</td> </tr> <tr> <td>100-199</td> <td>2.0</td> </tr> <tr> <td>≥ 200</td> <td>2.9</td> </tr> </tbody> </table> <p>MME=morphine milligram equivalents (50 MME/day = 50 mg/day Hydrocodone = 33 mg/day Oxycodone)</p>	MME/day	Relative risk of death	20-49	1.3	50-99	1.9	100-199	2.0	≥ 200	2.9
MME/day	Relative risk of death											
20-49	1.3											
50-99	1.9											
100-199	2.0											
≥ 200	2.9											
When starting opioids	Develop a formalized treatment plan <sup>2</sup> , informed consent and/or an opioid treatment agreement (controlled substance agreement). <b>[B4]</b> In Michigan, the <a href="#">Start Talking</a> form is mandated, and when signed, serves as attestation the patient received education. Perform baseline urine or serum drug screen at the time of starting therapy to assess concurrent substance use. <b>[B4]</b> Prescribe the lowest effective dose of immediate-release opioids (not extended-release) and no greater quantity than needed for the expected duration of pain severe enough to require opioids; three days or fewer for acute pain; more than seven days will rarely be needed. <b>[A4]</b> <a href="#">Michigan legislation</a> limits initial prescription to no more than seven (7) days. Use opioids as part of a pain management plan that includes instructions for tapering <sup>3</sup> , non-opioid medications and non-drug therapy, as appropriate. Discuss realistic goals for pain and function, and how opioid therapy will be discontinued if benefits do not outweigh risks. Avoid concurrent use of opioids with benzodiazepines, muscle relaxants, gabapentinoids, sedative hypnotics or alcohol <b>[A3]</b> , and educate patient about the dangers of mixing, due to the higher risk of death. <a href="#">Prescribe</a> patient and family naloxone when risk factors for overdose are present (e.g., history of overdose or substance use disorder, higher opioid dosages [50 MME/day], concurrent benzodiazepine use, or risk to other household members). <b>[A4]</b> Educate patient and family on <a href="#">naloxone use</a> . Call 911 immediately, give naloxone, then rescue breathing, followed by second dose of naloxone if no improvement within 2 minutes. May need to repeat doses. Patient should be seen immediately in a hospital Emergency Department due to return of overdose symptoms after naloxone wears off.											
If continuing opioids, or adjusting dose	Periodically re-evaluate pain and function (consider using an assessment tool such as <a href="#">PEG-3</a> ); recheck PDMP (MAPS). <b>[A4]</b> Continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety. <b>[A4]</b> Reassess known risks and realistic benefits throughout opioid therapy, including patient and clinician responsibilities for managing therapy. <b>[A3]</b> If benefits of therapy do not outweigh potential harms, optimize other therapies and work with patient to taper <sup>3</sup> to lower doses and discontinue. <b>[A4]</b> Perform urine drug testing to assess for prescribed medications as well as other controlled or illegal substances. <b>[B4]</b> Absence of prescribed medication may indicate diversion. An unexpected result at a minimum should prompt a patient-provider conversation and may warrant an appropriate confirmatory test. Perform testing at least annually, more frequently (every 3-6 months) if warranted. When considering increasing dosage to ≥ 50 MME/day, reassess evidence of individual benefits and risks. Avoid increasing dosage to ≥ 90 MME/day, carefully justify and document the decision. <b>[A3]</b> Patients treated long-term with > 100 MME/day should slowly be tapered <sup>3</sup> to lower doses. Consider referral to a pain specialist. Do not renew prescription for an opioid without clinical reassessment or screening for risks of OUD (see above). <b>[B4]</b>											
Identify Substance Use Disorder <sup>4</sup>	Manage or refer based on provider expertise in treating substance use disorder, patient willingness to be referred, and access. Use evidence-based treatment, such as Medication for Opioid Use Disorder/Medication Assisted Treatment (MOUD/MAT) <sup>4</sup> combined with behavioral therapy <b>[B4]</b> See <a href="#">MQIC Screening, Diagnosis and Referral for Substance Use Disorder guideline</a>											

1 [Michigan Opioid Resources Laws and Regulations](#)

2 [NIH National Institute on Drug Abuse Sample Patient Agreement Forms](#)

3 [CDC Pocket Guide: Tapering Opioids for Chronic Pain](#)

4 [Michigan Opioid Collaborative](#)

**Recommendation categories:** A = Applies to all persons; most patients should receive the recommended course of action; B = Individual decision making needed; different choices will be appropriate for different patients. Clinicians help patients arrive at a decision consistent with patient values and preferences and specific clinical situations. **Evidence type:** 1-Randomized clinical trials or overwhelming evidence from observational studies; 2-Randomized clinical trials with important limitations, or exceptionally strong evidence from observational studies; 3-Observational studies or randomized clinical trials with notable limitations; 4-Clinical experience and observations, observational studies with important limitations, or randomized clinical trials with several major limitations.

This guideline lists core management steps. It is based on Dowell D, Haegerich TM, Chou R. [CDC Prescribing Opioids for Chronic Pain](#) — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49; and [MI-OPEN Acute Care Opioid Treatment and Prescribing Recommendations: Summary of Selected Best Practices](#) June 26, 2018. Individual patient considerations and advances in medical science may supersede or modify these recommendations.

